Salivary Gland Neoplasms

Editors
Patrick J. Bradley
David W. Eisele

This volume in the book series 'Advances in Oto-Rhino-Laryngology' summarizes the current scientific knowledge of salivary gland neoplasms and illustrates recent advances in this clinical area. Chapters are authored by world renowned experts who cover the full breadth of salivary gland neoplasms, from benign to malignant, primary to secondary, and pediatric to adult. This comprehensive review highlights the outcome of treatments as well as the classification, diagnosis, and management of salivary gland neoplasms. It also includes a commentary on the future perspective necessary for improvement.

All clinicians, both surgical and non-surgical, involved in the diagnosis and treatment of patients with symptoms and diseases of the salivary gland, will find this book indispensable reading. It is also a beneficial educational resource for clinicians, students, and experts in the field.

Contents

Preface: Bradley, P.J.; Eisele, D.W.
- Classification of Salivary Gland Neoplasms: Bradley, P.J.
- Frequency and Histopathology by Site, Major Pathologies, Symptoms and Signs of Salivary Gland Neoplasms: Bradley, P.J.
- Molecular Pathology and Biomarkers: Ha, P.K.; Stenman, G.
- Evaluation: Imaging Studies: Kontzialis, M.; Glastonbury, C.M.; Aygun, N.
- Evaluation: Fine Needle Aspiration Cytology, Ultrasound-Guided Core Biopsy and Open Biopsy Techniques: Howlett, D.C.; Triantafyllou, A.
- Facial Nerve Monitoring: Guntinas-Lichius, O.; Eisele, D.W.
- Surgery for Benign Salivary Neoplasms: Gillespie, M.B.; Iro, H.
- Recurrent Benign Salivary Gland Neoplasms: Witt, R.L.; Nicolai, P.
- Prognostic Scoring for Malignant Salivary Gland Neoplasms: Vander Poorten V.; Guntinas-Lichius, O.
- Surgery for Primary Malignant Parotid Neoplasms: Deschler, D.G.; Eisele, D.W.
- Metastatic Cancer to the Parotid: Clark, J.; Wang, S.
- Surgery for Malignant Submandibular Gland Neoplasms: Silver, N.L.; Chinn, S.B.; Bradley, P.J.; Weber, R.S.
- Surgery for Malignant Siblingual and Minor Salivary Gland Neoplasms: Bradley, P.J.; Ferris, R.L.
- Facial Reconstruction and Rehabilitation: Guntinas-Lichius, O.; Genthier, D.J.; Byrne, P.J.
- Management of Regional Metastases of Malignant Salivary Gland Neoplasms: Medina, J.; Zbären, P.; Bradley, P.J.
- Indications for Salivary Gland Radiotherapy: Thomson, D.J.; Slevin, N.J.; Mendenhall, W.M.
- Chemotherapy and Targeted Therapy: Sen, M.; Prestwick, R.
- Management of Inoperable Malignant Neoplasms: Kiess, A.P.; Quon, H.
- Management of Recurrent Malignant Salivary Neoplasms: Merdad, M.; Richmon, J.D.; Quon, H.
- Salivary Gland Neoplasms in Children and Adolescents: Bradley, P.J.; Eisele, D.W.
- Distant Metastases and Palliative Care: Glazer, T.A.; Shuman, A.G.
- Quality of Life after Salivary Gland Surgery: Wax, M.K.; Talmi, Y.P.

Author Index / Subject Index

The easiest way to order: www.karger.com/adorl

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f. +41 61 306 12 34
www.karger.com
Contents

See the journal website for contents
**Submission**

Original papers and reviews written in English are considered for publication. Manuscripts should be submitted to Oncology online and must be accompanied by a cover letter signed by the submitting/corresponding author on behalf of all co-authors. Assurance should be given that the manuscript is not under simultaneous consideration by any other publication. For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at www.karger.com/ocl, where you will also find a link to the Submission Website. Names, postal and e-mail addresses of at least four experts in the appropriate area of research must accompany each manuscript. Selected scientists will be invited to act as referees. Referees suggested should not be from the same institution as the author and should have expert knowledge of the subject. Should you have any problems with your submission, please contact:

Dr. M. Markman  
S. Karger AG  
Editorial Office 'Oncology'  
CH–4009 Basel (Switzerland)  
Tel. +41 61 306 1359  
Fax +41 61 306 1434  
E-Mail ocl@karger.com

Mailing address for courier deliveries only:  
Allschwilerstr. 10  
CH–4055 Basel (Switzerland)

**Conditions**

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. The editors reserve the right to improve style and, if necessary, return the manuscript for rewriting to the author. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Karger upon acceptance. Accepted papers become the permanent property of Oncology and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author's responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Abstracts of papers originating from non-English speaking countries must be revised by a professional linguistic reviewer and it must be evident from the covering letter that this has been done. The editor reserves the right to reject papers based on priorities and space availability in the journal.

**Conflicts of Interest**

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the text of the article.

**Ethical and Legal Prerequisites**

Manuscripts involving examinations of human subjects must include a statement that the trial protocol has been approved by an ethical committee and thus meets the standards of the Declaration of Helsinki in its revised version of 1975 and its amendments of 1983, 1989, and 1996 [JAMA 1997;277:925–926]. Accordingly, the subject's informed consent has to be mentioned in the manuscript. Information suitable to reveal the subject's identity is to be avoided.

**Plagiarism Policy**

Whether intentional or not, plagiarism is a serious violation. We define plagiarism as a case in which a paper reproduces another work with at least 25% similarity and without citation. If evidence of plagiarism is found before/after acceptance or after publication of the paper, the author will be offered a chance for rebuttal. If the arguments are not found to be satisfactory, the manuscript will be retracted and the author sanctioned from publishing papers for a period to be determined by the responsible Editor(s).

**Categories of Manuscripts**

**Reviews** are comprehensive, state-of-the-art analyses and investigations of important clinical problems. Reviews must include a critical discussion of the reported data and give a clear conclusion with the potential impacts on the standard of care. Reviews may be invited by the Editor, or they may be unsolicited submissions. Reviews are not subject to page charges. The maximum length of manuscripts in this category will be 5,000 words for text and tables (a table = 250 words per page), with a maximum of 5 tables and 50 references.

**Clinical Studies and Clinical Translational Research Articles** are full-length research papers which will be considered for the journal. These articles cover topics relevant to clinical and translational studies in all oncological fields. Note that manuscripts presenting laboratory-based research efforts must address a clinically relevant issue (Translational Research).

**Short Communications** will focus on descriptions of important toxicities of novel therapies and highly unique oncology-related medical management issues. The maximum length of manuscripts in this category will be 1,000 words.

**Clinical Trial Notes** are designed for brief discussions of clinical trials, with a particular focus on phase 1, phase 1/2, and phase 2 studies. Priority in this section will not be for studies with a ‘positive result’ but rather for well-conceived and conducted clinical research efforts. The maximum length of manuscripts submitted in this category will be 1,500 words, with a maximum of 2 tables and 1 figure. The paper should be divided into four sections: Introduction, Methods, Results, Discussion. Note that all manuscripts submitted in this category will undergo rapid review for acceptance or rejection.

**Reducing the Worldwide Burden of Cancer** are country reports describing a variety of regional, national or international efforts that focus on the unique aspects of the epidemiology of cancer, and the delivery of educational messages, preventive services, and oncology-related care within the developing world. Papers submitted for this section benefit from a higher quota of free pages. There are no page charges for papers of 8 or fewer printed pages. Each additional complete or partial page is charged to the author at CHF 325.00.

**Editorials** are commentaries on current topics or on papers published elsewhere in the issue. Word count limit is 1,500 and 10 references are allowed. They are usually invited by the Editor.

Letters addressed to the Editor are encouraged if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. But letters on general scientific or medical subjects in oncology are also welcome. The length should not exceed 300 words.

**Arrangement**

**Title page:** The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as a running head.

**Full address:** The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail addresses.

**Key words:** Please supply 3–10 key words in English that reflect the content of the paper.

**Abstract:** Papers submitted to the sections Reviews, Clinical Studies, Clinical Translational Research Articles, Clinical Trial Notes and Reducing the Worldwide Burden of Cancer need an abstract of up to 200 words. Abstracts are recommended, but optional, for Short Communications and Editorials. Abstracts of papers submitted for publication that have clinical implications using human materials should be structured with subheadings as follows: Objective(s), Methods, Results, Conclusion(s).

**Footnotes:** Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

**Tables and illustrations:** Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate pages. Tables require a heading and figures a legend, also prepared on separate pages. Tables require a heading and figures a legend, also prepared on separate pages. Figure files must not be embedded in a document file but submitted separately (see detailed instructions on the Submission Website at www.karger.com/ocl).
Oncology

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 960.00 per page.

References

In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as [unpublished data] and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples

(b) Papers published only with DOI numbers: Thoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in thearides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in the... . doi: https://karger.figshare.com/doi/10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Multimedia files and other supplementary files, directly relevant but not essential to the conclusions of a paper, enhance the online version of a publication and increase its visibility on the web. These files will undergo editorial review. The Editors reserve the right to limit the scope and length of the supplementary material. Multimedia and supplementary material should meet production quality standards for publication without the need for any modification or editing. Files should not exceed 10 MB in size. Figures and tables need to have titles and legends, and all files should be supplied separately and labeled clearly. All supplementary material should be referred to in the main text. A DOI number will be assigned to supplementary material and it will be hosted online at https://karger.figshare.com under a CC BY license. Authors will be charged a processing fee of CHF 250.00 for supplementary material.

Self-Archiving/Green Open Access

Karger permits authors to archive their pre-prints (i.e. pre-peer review) or post-prints (i.e. accepted manuscript, including figure legend but before production) on their personal or their institution’s internal website. In addition, authors may post their accepted manuscripts in public Open Access repositories and scientific networks (e.g. ResearchGate or Mendeley) no earlier than 12 months following publication of the final version of their article. For all self-archiving, the posted manuscripts must:

• Be used for noncommercial purposes only
• Be linked to the final version on www.karger.com

Include the following statement:

“This is the peer-reviewed but unedited manuscript version of the following article: [insert full citation, e.g. Cytogenet Genome Res 2014;142:227–238 (DOI: 10.1159/000361001)]. The final, published version is available at http://www.karger.com/doi/insert DOI number.”

It is the author’s responsibility to fulfill these requirements.

For papers published online first with a DOI number only, full citation details must be added as soon as the paper is published in its final version. This is important to ensure that citations can be credited to the article.

Funding Organizations (NIH etc.)

The U.S. National Institutes of Health (NIH) Public Access Policy mandates that accepted, peer-reviewed manuscripts are archived in its digital database, PubMed Central (PMC), within 12 months of the official publication date. As a service to authors, Karger submits NIH-funded articles to PMC on behalf of the authors immediately upon publication. The NIH assigns a PMCID within approximately 1 month and the manuscript will appear in PMC after a 12-month embargo. For authors making their paper Open Access through Author’s Choice™, the embargo will be overridden, thereby accelerating the accessibility of the article. Karger also complies with other funders’ requirements (including Wellcome Trust and RCUK) for submission to PMC. Authors should include information on their grants and other funders’ requirements (including Wellcome Trust and RCUK) in the acknowledgements section of their papers.

Page Charges

There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.00. The allotted size of a paper is equal to approx. 7 manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer's errors are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

KARGER

© 2016 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com

The Guidelines for Authors are available at:
www.karger.com/ocl_Guidelines
48th Congress of the International Society of Paediatric Oncology

October 19 - 22, 2016
www.kenes.com/siop

REGISTER TODAY

Kenes International
7, rue Francois-Versonnex,
C.P. 6053, 1211 Geneva 6 Switzerland
Tel: +41 22 906 9178 | Fax: +41 22 732 2607
Join us at the
2016 NCRI Cancer Conference
The UK’s largest cancer research meeting

Take advantage of
earlybird rates
Deadline:
30 June 2016

Late breaking
abstract submission opener
1 August 2016

Topics include:
- Science journalism
- Radiobiology and prostate cancer
- Immunotherapy
- APOBECs and relevance to cancer
- Phase III trials
- Surgical oncology
  ... and many more

Confirmed speakers include:
- Kat Arney
  Freelance science writer and broadcaster
  London, UK
- Rob Bristow
  University of Toronto, Canada
- David Currow
  Flinders University, Australia
- Lieping Chen
  Yale School of Medicine, USA
- Iain Hagan
  Cancer Research UK Manchester Institute, UK
- Reuben Harris
  University of Minnesota, USA
- Mark Krasnow
  Stanford University, USA
- Charles Rudin
  Memorial Sloan Kettering Cancer Center, USA
- Alex Snyder
  Memorial Sloan Kettering Cancer Center, USA
- Jennifer Wargo
  MD Anderson Cancer Center, USA

conference.ncri.org.uk

@NCRI  #NCRI2016
Onco Update Europe 2016

2nd European Update Congress in Oncology
Budapest, 25-26 November 2016

- Complete scientific update by European experts
- Unbiased cutting-edge study results
- Ensured practical relevance

Scientific board
Florian Lordick, Germany
Silke Gillessen, Switzerland
Gianpaolo Tortora, Italy
Marcel Verheij, Netherlands

Registration and further information
www.onco-update-europe.eu
The challenges of personalised medicine integration into clinical practice and daily care

Access for All: A Personalised Approach

Editors
Denis Horgan
Angela Brand
Kapaetti Satyamoorthy

There is a recognised need to define barriers and develop putative solutions to the issue of patient access to personalised medicine across the EU. To meet this need, the Brussels-based European Alliance for Personalised Medicine (EAPM) assembled a multi-stakeholder panel to address the topics. Certain key challenges form the basis for this issue of Public Health Genomics: The authors outline them and present potential solutions to help embed personalised medicine into national health care systems. Part of the access problem concerns the EU’s directive on patients’ rights to cross-border care. The effectiveness of the directive depends on collaboration at the European level. Unfortunately that sort of collaboration is in very short supply – a deficiency that threatens to undermine what is a well-intentioned initiative. Meanwhile, challenging fiscal times and an ageing population of 500 million potential patients across the EU’s 28 Member States, are making health care in Europe more expensive than ever. People are living longer and well, in most cases, be treated for not just one but several ailments during their lifetime. As such, a publication such as this is a valuable resource for EU/national politicians, health care planners, patients, medical professionals, and researchers.

Contents
Editorial
Access for All: A Personalised Approach: Horgan, D.

- Shooting for the Moon or Flying Too Near the Sun? Crossing the Value Rubicon in Precision Cancer Care: Lawler, M.; French, D.; Henderson, R.; Aggarwal, A.; Sullivan, R.
- Personalised Medicine and Scarce Resources: A Discussion of Ethical Chances and Challenges from the Perspective of the Capability Approach: Brall, C.; Schröder-Bäck, P.

Author Index/Subject Index

The easiest way to order: www.karger.com/phg

Karger – Medical and Scientific Publishers
CH-4009 Basel, Switzerland
orders@karger.com, f. +41 61 306 12 34
www.karger.com
The first oncology journal dedicated exclusively to case reports

Case Reports in Oncology

www.karger.com/cro

- open access
- peer-reviewed
- fast online publication

This peer-reviewed online-only journal publishes original case reports covering the entire spectrum of oncology, including prevention, diagnosis, treatment, toxicities of therapy, supportive care, quality-of-life, and survivorship issues. The journal will also accept case reports dealing with the use of novel technologies, both in the arena of diagnosis and treatment. Supplementary material is welcomed. The intent of the journal is to provide clinicians and researchers with a tool to disseminate their personal experiences to a wider public as well as to review interesting cases encountered by colleagues all over the world. Universally used terms can be searched across the entire growing collection of case reports, further facilitating the retrieval of specific information.

Following the open access principle, the entire contents can be retrieved at no charge, guaranteeing easy access to this valuable source of anecdotal information at all times.

More information at www.karger.com/cro
'Liquid-Tumor Biopsies' and the Future of Solid Tumor Oncology
Markman, M. (Philadelphia, Pa.)

Molecular Targets in Advanced Therapeutics of Cancers: The Role of Pharmacogenetics
Abubakar, M.B. (Kota Bharu/Sokoto); Gan, S.H. (Kota Bharu)

Global Epidemiology of Head and Neck Cancers: A Continuing Challenge
Gupta, B.; Johnson, N.W. (Gold Coast, Qld.); Kumar, N. (Pune)

A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study)
Yoshida, M. (Osaka); Takagane, A. (Hakodate); Miyake, Y. (Minoh); Shimada, K. (Kanagawa); Nagata, N. (Kitakyushu);
Sato, A. (Tokyo); Ogata, Y. (Kurume); Fukunaga, M. (Osaka);
Otsuka, K. (Morioka); Takahashi, T. (Gifu); Matsumoto, H. (Miyazaki);
Kagimura, T. (Kobe); Tsuji, A. (Kochi)

Gastric Cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis
Otsu, H.; Iimori, M.; Ando, K.; Saeki, H. (Fukuoka); Aishima, S. (Fukuoka/Saga); Oda, Y.; Morita, M. (Fukuoka); Matsuo, K. (Aichi);
Kitao, H.; Oki, E.; Maehara, Y. (Fukuoka)

Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer

Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer
Arora, R.; Arkenau, H.-T.; Widschwendter, M.; MacDonald, N.;
Ledermann, J.A.; McCormack, M.; Kristeleit, R.S. (London)

Reducing the Worldwide Burden of Cancer

Metastatic Gastroesophageal Adenocarcinoma Patients Treated with Systemic Therapy Followed by Consolidative Local Therapy: A Nomogram Associated with Long-Term Survivors
Shiozaki, H.; Slack, R.S.; Chen, H.-C.; Elimova, E.;
Planjery, V.; Charalampakis, N.; Wadhwa, R.; Shimodaira, Y.;
Blum-Murphy, M.; Rogers, J.E.; Maru, D.M.;
Matamoros Jr., A.; Sagebiel, T.; Estrella, J.S.; Das, P.;
Hofstetter, W.L.; Mares, J.E.; Mizrak Kaya, D.; Harada, K.; Lin, Q.;
Minsky, B.D.; Badgwell, B.D.; Ajani, J.A. (Houston, Tex.)